A detailed history of Sargent Investment Group, LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Sargent Investment Group, LLC holds 2,299 shares of LLY stock, worth $2.08 Million. This represents 0.4% of its overall portfolio holdings.

Number of Shares
2,299
Previous 2,161 6.39%
Holding current value
$2.08 Million
Previous $1.26 Million 42.02%
% of portfolio
0.4%
Previous 0.28%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$592.2 - $792.28 $81,723 - $109,334
138 Added 6.39%
2,299 $1.79 Million
Q4 2023

Feb 05, 2024

SELL
$525.19 - $619.13 $152,305 - $179,547
-290 Reduced 11.83%
2,161 $1.26 Million
Q3 2023

Nov 13, 2023

BUY
$434.7 - $599.3 $59,553 - $82,104
137 Added 5.92%
2,451 $1.32 Million
Q2 2023

Jul 31, 2023

BUY
$350.74 - $468.98 $53,312 - $71,284
152 Added 7.03%
2,314 $1.09 Million
Q1 2023

May 02, 2023

BUY
$310.63 - $364.82 $10,250 - $12,039
33 Added 1.55%
2,162 $742,000
Q4 2022

Jan 31, 2023

BUY
$321.55 - $374.67 $8,038 - $9,366
25 Added 1.19%
2,129 $778,000
Q3 2022

Oct 26, 2022

SELL
$296.48 - $337.87 $34,095 - $38,855
-115 Reduced 5.18%
2,104 $701,000
Q2 2022

Jul 26, 2022

SELL
$278.73 - $327.27 $36,234 - $42,545
-130 Reduced 5.53%
2,219 $719,000
Q4 2021

Feb 11, 2022

SELL
$224.85 - $279.04 $17,988 - $22,323
-80 Reduced 3.29%
2,349 $649,000
Q2 2021

Aug 05, 2021

SELL
$180.55 - $233.54 $3,611 - $4,670
-20 Reduced 0.82%
2,429 $558,000
Q1 2021

May 04, 2021

BUY
$164.32 - $212.72 $24,648 - $31,908
150 Added 6.52%
2,449 $458,000
Q3 2020

Nov 12, 2020

BUY
$146.22 - $169.13 $29,244 - $33,826
200 Added 9.53%
2,299 $340,000
Q2 2020

Aug 11, 2020

BUY
$136.42 - $164.18 $66,163 - $79,627
485 Added 30.05%
2,099 $343,000
Q1 2020

May 12, 2020

BUY
$119.05 - $147.35 $192,146 - $237,822
1,614 New
1,614 $224,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $862B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Sargent Investment Group, LLC Portfolio

Follow Sargent Investment Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sargent Investment Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Sargent Investment Group, LLC with notifications on news.